VEGFA and age-related macular degeneration: Final visual acuity of group 2 and 3 have further deteriorated than group 1 AMD cases indicating the longitudinal implication of genetic susceptibility (especially through LIPC and APOE) and response towards anti-VGEF treatment (also the number of anti-VEGF injections).